# Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC

> **NCT07035392** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhangzhou Municipal Hospital** · enrollment: 32 (estimated)

## Conditions studied

- Adebrelimab (SHR-1316)
- NSCLC
- Chemotherapy

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** chemotherapy

## Key facts

- **NCT ID:** NCT07035392
- **Lead sponsor:** Zhangzhou Municipal Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-20
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07035392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07035392, "Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07035392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*